Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group

Basit Öğe Kaydı
dc.authoridCetinkaya, Hakki/0000-0001-9527-3885
dc.authoridtatar, erhan/0000-0002-5068-4231
dc.authoridOruc, Aysegul/0000-0002-0342-9692
dc.authorwosidDirim, Ahmet Burak/ABA-8890-2020
dc.contributor.authorOruc, Aysegul
dc.contributor.authorSumnu, Abdullah
dc.contributor.authorTurkmen, Aydin
dc.contributor.authorBasturk, Taner
dc.contributor.authorCebeci, Egemen
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorCetinkaya, Hakki
dc.date.accessioned2024-06-12T11:03:40Z
dc.date.available2024-06-12T11:03:40Z
dc.date.issued2024
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackgroundImmunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye.MethodThe data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 +/- 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed.ResultsRemission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission.ConclusionCS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.en_US
dc.identifier.doi10.1080/0886022X.2024.2341787
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue1en_US
dc.identifier.pmid38637275en_US
dc.identifier.scopus2-s2.0-85190809699en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1080/0886022X.2024.2341787
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21748
dc.identifier.volume46en_US
dc.identifier.wosWOS:001205022800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIga Nephropathyen_US
dc.subjectImmunosuppressive Treatmenten_US
dc.subjectTurkiyeen_US
dc.subjectRemissionen_US
dc.subjectOutcomeen_US
dc.subjectOral Methylprednisoloneen_US
dc.subjectSupportive Careen_US
dc.subjectPathogenesisen_US
dc.subjectPrednisoneen_US
dc.subjectOutcomesen_US
dc.subjectTherapyen_US
dc.titleImmunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu